噻托溴铵联合沙美特罗/丙酸氟替卡松治疗慢性阻塞性肺疾病稳定期患者的疗效观察  

Tiotropium bromide combined salmeterol/fluticasone propionate for the treatment in patients with stable chronic obstructive pulmonary disease

作　　者：赵正宇 张爱观[2] 

机构地区：[1]平湖市第一人民医院呼吸科,314200 [2]平湖市中医院呼吸科,314200

出　　处：《国际呼吸杂志》2011年第7期490-492,共3页International Journal of Respiration

摘　　要：目的 观察沙美特罗/丙酸氟替卡松（舒利迭）联合噻托溴铵粉吸入剂（思力华）对慢性阻塞性肺疾病（COPD）缓解期的治疗效果.方法 采用随机、双肓的方法将85例COPD患者分为观察组和对照组,观察组A组给予噻托溴铵和沙美特罗/丙酸氟替卡松治疗,对照组B组给予沙美特罗/内酸氟替卡松治疗.分别对两组患者治疗前后的呼吸困难的评分、肺功能的检测和6分钟步行距离（6MWD）的情况进行比较.结果 治疗3个月后,与对照组比较,观察组肺功能指标FEV1、FEV1/FVC%、生活质量评分及6MWD,差异有统计学意义（P＜0.05）.结论 噻托溴铵与沙美特罗/丙酸氟替卡松联合吸入治疗COPD,疗效优于沙美特罗替卡松单药治疗.Objective To evaluate the effects of tiotropium bromide combined salmeterol/fluticasone propionate （SFC） for the treatment in patients with stable chronic obstructive pulmonary disease（COPD）. Methods A randomized, double blind clinical trial was conducted in 85 patients with stable COPD. Group A was given tiotropium bromide combined with SFC,Group B was given SFC,the St George＇s respiratory questionnaire （SGRQ）, pulmonary function and 6 minute walk distance （6-MWD）was conducted at baseline, 3 monthes after treatment. Results FEV1 , FEV1/FVC%, SGRQ score and 6-MWD in combined group A were significantly superior to those of control group B at 3 monthes after treatment （all P 〈0.05）. Conclusions Tiotropium bromide combined SFC could further advance efficacy than SFC for the treatment in patients with stable COPD.

关 键 词：慢性阻塞性肺疾病 噻托溴铵 沙美特罗/丙酸氟替卡松 肺功能 

分 类 号：R563.9[医药卫生—呼吸系统]